Evidence map›Paper›PMID 41341741›Full record

ReviewChronic diseases and translational medicine2025

Gankyrin-Protein Interactions in GI Cancers: A Novel Target of New Therapeutics.

Shuang Li, Yuky Lam, Aaron Muth, Zhe-Sheng Chen, Shanzhi Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Chronic diseases and translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shuang LiDivision of Digestive and Liver Diseases, Irving Cancer Research Center Columbia University Medical Center New York New York USA.
Yuky LamDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences St. John's University Jamaica New York USA.
Aaron MuthDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences St. John's University Jamaica New York USA.
Zhe-Sheng ChenDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences St. John's University Jamaica New York USA.ORCID https://orcid.org/0000-0002-8289-097X
Shanzhi WangDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences St. John's University Jamaica New York USA.ORCID https://orcid.org/0000-0002-7068-0756

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gankyrin (PSMD10) is a 25 kDa oncogenic protein and regulatory subunit of the 26S proteasome, characterized by a sevenfold ankyrin repeat domain. Gankyrin is overexpressed in various malignancies, particularly gastrointestinal (GI) cancers. Gankyrin contributes to tumorigenesis by modulating key signaling pathways and engaging in oncogenic protein-protein interactions with tumor suppressors, including p53 and Rb, thereby promoting cell proliferation, metastasis, and resistance to treatment. Recent advances have shed light on the structural basis of gankyrin's molecular interactions, its potential as a diagnostic and prognostic biomarker, and emerging therapeutic strategies. Together, targeting gankyrin represents a promising strategy for precision oncology in GI cancers.

Indexed as

gankyrininhibitorsMDM2

Identifiers

PMID41341741
PMCPMC12670975

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.